Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in Generalized Pustular Psoriasis flare
NCT05239039Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of spesolimab in generalized pustular psoriasis (GPP) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Adverse Events at 17 weeks. Started Mar 2022; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05239039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239039.